pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include Asthma, Idiopathic pulmonary fibrosis (IPF), Mild to moderate asthma, Pulmonary fibrosis, Chronic obs
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
Cardiovascular safety assessment of Tanimilast in healthy volunteers
Phase 1 · other · This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.
Cardiovascular safety assessment of Tanimilast in healthy volunteers for This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers. is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Internal code CLI-06001AA1-09
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chiesi Farmaceutici S.p.A
- Phase
- Phase 1
- Modality
- other
- Indication
- This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.
- Status
- active
- Trials
- 1